{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+B&page=11",
    "query": {
      "intervention": "Formulation B",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 523,
    "total_pages": 53,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+B&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+B&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T08:00:38.335Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01221519",
      "title": "A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "High Blood Sugar"
      ],
      "interventions": [
        {
          "name": "AZD1656",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2010-09",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2012-01-19",
      "last_synced_at": "2026-10-20T08:00:38.335Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01221519"
    },
    {
      "nct_id": "NCT03078556",
      "title": "Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir + Lamivudine FDC Formulation 1",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir + Lamivudine FDC Formulation 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 154,
      "start_date": "2017-03-27",
      "completion_date": "2017-08-18",
      "has_results": true,
      "last_update_posted_date": "2019-02-21",
      "last_synced_at": "2026-10-20T08:00:38.335Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03078556"
    },
    {
      "nct_id": "NCT01559272",
      "title": "A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Paliperidone IR (Period 1)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel A: treatment group 1)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel A: treatment group 2)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel B: treatment group 1)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel B: treatment group 2)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel B: treatment group 3)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel B: treatment group 4)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel B: treatment group 5)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F016",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel D: treatment group 1)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel D: treatment group 2)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel D: treatment group 3)",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone palmitate F015 (Panel D: treatment group 4)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 328,
      "start_date": "2008-02-21",
      "completion_date": "2014-05-24",
      "has_results": false,
      "last_update_posted_date": "2017-09-18",
      "last_synced_at": "2026-10-20T08:00:38.335Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "National City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01559272"
    },
    {
      "nct_id": "NCT02748694",
      "title": "Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "TAK-041",
          "type": "DRUG"
        },
        {
          "name": "TAK-041 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 114,
      "start_date": "2016-05-09",
      "completion_date": "2019-09-22",
      "has_results": true,
      "last_update_posted_date": "2021-03-19",
      "last_synced_at": "2026-10-20T08:00:38.335Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02748694"
    },
    {
      "nct_id": "NCT04991571",
      "title": "Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Zibotentan (Treatment A)",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin (Treatment A)",
          "type": "DRUG"
        },
        {
          "name": "Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)",
          "type": "DRUG"
        },
        {
          "name": "Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 27,
      "start_date": "2021-07-29",
      "completion_date": "2021-10-22",
      "has_results": false,
      "last_update_posted_date": "2021-11-23",
      "last_synced_at": "2026-10-20T08:00:38.335Z",
      "location_count": 1,
      "location_summary": "Brooklyn, Maryland",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04991571"
    },
    {
      "nct_id": "NCT01860937",
      "title": "T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed B-Cell Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "leukapheresis or collection of PBMCs",
          "type": "PROCEDURE"
        },
        {
          "name": "cyclophosphamide based chemotherapy regimens",
          "type": "DRUG"
        },
        {
          "name": "modified T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "Up to 26 Years"
      },
      "enrollment_count": 23,
      "start_date": "2013-05",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-10-20T08:00:38.335Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01860937"
    },
    {
      "nct_id": "NCT03234036",
      "title": "A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK2838232 100 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "GSK2838232 50 mg capsule",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir 100 mg tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo for GSK2838232 tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 26,
      "start_date": "2017-08-02",
      "completion_date": "2017-11-10",
      "has_results": true,
      "last_update_posted_date": "2020-10-28",
      "last_synced_at": "2026-10-20T08:00:38.335Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03234036"
    },
    {
      "nct_id": "NCT01375244",
      "title": "Comparative Bioavailability Study of Lisinopril Tablets, 10 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Lisinopril",
          "type": "DRUG"
        },
        {
          "name": "Zestril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Par Pharmaceutical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 36,
      "start_date": "1999-06",
      "completion_date": "1999-10",
      "has_results": false,
      "last_update_posted_date": "2011-06-17",
      "last_synced_at": "2026-10-20T08:00:38.335Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01375244"
    },
    {
      "nct_id": "NCT01980953",
      "title": "A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "GDC-0032 Phase III Tablet",
          "type": "DRUG"
        },
        {
          "name": "GDC-0032 Tablet",
          "type": "DRUG"
        },
        {
          "name": "GDC-0032 Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 76,
      "start_date": "2013-11",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2017-02-01",
      "last_synced_at": "2026-10-20T08:00:38.335Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01980953"
    },
    {
      "nct_id": "NCT04745767",
      "title": "A Study of Different Forms of TAK-994 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "TAK-994",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 54,
      "start_date": "2021-02-16",
      "completion_date": "2021-04-05",
      "has_results": false,
      "last_update_posted_date": "2021-04-22",
      "last_synced_at": "2026-10-20T08:00:38.335Z",
      "location_count": 2,
      "location_summary": "Tempe, Arizona • Lincoln, Nebraska",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04745767"
    }
  ]
}